“Ritonavir Boosting in Antiviral Therapies Against SARS-CoV-2 Affects Atorvastatin but Not Rosuvastatin Pharmacokinetics”

https://pubmed.ncbi.nlm.nih.gov/38112932

A short course of Ritonavir used as a booster in antiviral therapies against SARS-CoV-2 significantly increases atorvastatin exposure, requiring dose adjustments, but does not affect rosuvastatin pharmacokinetics.